These statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “will,” “expect,” “continue," “scheduled,” “plans,” “intend,” and similar expressions are generally intended to identify forward-looking statements. This press release includes statements that may constitute "forward-looking statements", including expectations and other statements regarding Akorn's expansion into the OTC market and other goals and plans.
Additional information is available on Akorn’s website at Cautionary Note Regarding Forward-Looking Statements (OTCQB Venture Market: INNV).”įluticasone propionate nasal spray USP, 50 mcg per spray is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older.įluticare® is a registered trademark of Innovus Pharmaceuticals, Inc.Īkorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois Somerset, New Jersey Amityville, New York Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Among other private label possibilities, we have a supply agreement in place for Fluticare® through Innovus Pharmaceuticals, Inc. Food and Drug Administration (FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC).ĭouglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are excited to add to our Fluticasone franchise and look forward to expanding into the over-the-counter (OTC) market. LAKE FOREST, Ill., Ap(GLOBE NEWSWIRE) - Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S.
0 kommentar(er)
